DE69432033T2 - Adrenomedullin - Google Patents

Adrenomedullin

Info

Publication number
DE69432033T2
DE69432033T2 DE69432033T DE69432033T DE69432033T2 DE 69432033 T2 DE69432033 T2 DE 69432033T2 DE 69432033 T DE69432033 T DE 69432033T DE 69432033 T DE69432033 T DE 69432033T DE 69432033 T2 DE69432033 T2 DE 69432033T2
Authority
DE
Germany
Prior art keywords
proam
proadrenomedullin
peptide
adrenomedullin
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69432033T
Other languages
English (en)
Other versions
DE69432033D1 (de
Inventor
Kazuo Kitamura
Kenji Kangawa
Hisayuki Matsuo
Tanenao Eto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of DE69432033D1 publication Critical patent/DE69432033D1/de
Publication of DE69432033T2 publication Critical patent/DE69432033T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/003—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by transforming the C-terminal amino acid to amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69432033T 1993-04-26 1994-04-25 Adrenomedullin Expired - Lifetime DE69432033T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP9985693 1993-04-26
JP18310793 1993-07-23
JP29873693 1993-11-29
JP6079035A JP2774769B2 (ja) 1993-04-26 1994-04-18 アドレノメデュリン

Publications (2)

Publication Number Publication Date
DE69432033D1 DE69432033D1 (de) 2003-02-27
DE69432033T2 true DE69432033T2 (de) 2003-09-25

Family

ID=27466245

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432033T Expired - Lifetime DE69432033T2 (de) 1993-04-26 1994-04-25 Adrenomedullin

Country Status (9)

Country Link
US (4) US5639855A (de)
EP (1) EP0622458B1 (de)
JP (1) JP2774769B2 (de)
KR (1) KR100312443B1 (de)
AT (1) ATE231553T1 (de)
CA (1) CA2122112C (de)
DE (1) DE69432033T2 (de)
DK (1) DK0622458T3 (de)
ES (1) ES2191674T3 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0845036B1 (de) 1995-08-18 1999-06-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
US6440421B1 (en) * 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
JP2001524454A (ja) 1997-09-26 2001-12-04 オークランド ユニサーヴィスィズ リミテッド 治療方法
WO2000078339A1 (fr) * 1999-06-23 2000-12-28 Shionogi & Co., Ltd. Inhibiteurs de contractions uterines
DE60027168T2 (de) 1999-06-23 2007-01-11 Shionogi & Co., Ltd. Adrenomedullin zur behandlung von störungen des harnlassens
FR2821080B1 (fr) * 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
JPWO2003078460A1 (ja) * 2002-03-19 2005-07-14 株式会社オンコレックス ペプチド、該ペプチドを含有する医薬組成物及び癌治療用医薬組成物
US20040121375A1 (en) * 2002-09-30 2004-06-24 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
CA2501282C (en) * 2002-10-04 2012-12-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasoregulating compounds and methods of their use
US7462593B2 (en) * 2002-11-07 2008-12-09 Us Gov Health & Human Serv Compositions and methods for promoting angiogenesis
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
CA2539467C (en) * 2003-09-08 2012-11-13 Frank Cuttitta Non-peptide agonists and antagonists of adrenomedullin and gastric releasing peptide
WO2005103720A1 (en) * 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
US8703693B2 (en) * 2004-03-31 2014-04-22 The Feinstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
AU2005231395B2 (en) 2004-03-31 2011-06-16 The Fernstein Institute For Medical Research Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
EP1844158A4 (de) * 2004-12-06 2010-09-08 Univ Johns Hopkins Biomarker für entzündliche darmerkrankung
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
JPWO2006095711A1 (ja) * 2005-03-07 2008-08-14 国立循環器病センター総長 アドレノメデュリンを用いて障害組織を再生または修復する方法
JP4505640B2 (ja) * 2005-04-12 2010-07-21 国立大学法人 宮崎大学 心筋障害の予防又は治療剤
EP1878789A4 (de) * 2005-04-14 2008-08-27 Japan As Represented By Genera Aus fett stammende vorläuferzelle und verwendung davon
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
WO2007062676A1 (en) 2005-12-01 2007-06-07 B.R.A.H.M.S. Aktiengesellschaft Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
CN101945659A (zh) 2008-02-19 2011-01-12 国立大学法人旭川医科大学 肾上腺髓质素产生增强剂
US9629895B2 (en) * 2011-01-12 2017-04-25 University Of Miyazaki Method for prevention or treatment of intractable inflammatory bowel disease
ES2387240B2 (es) * 2011-01-31 2013-04-26 Fundación Rioja Salud Péptido capaz de aumentar la velocidad de desplazamiento de una kinesina o su homóloga funcional sobre microtúbulos.
RU2662671C2 (ru) * 2011-11-16 2018-07-26 Адреномед Аг АНТИТЕЛО К АДРЕНОМЕДУЛЛИНУ (ADM) ИЛИ ФРАГМЕНТ АНТИ-ADM АНТИТЕЛА, ИЛИ АНТИ-ADM HE-Ig КАРКАС ДЛЯ ПРИМЕНЕНИЯ В ТЕРАПИИ
SG10202006318TA (en) 2011-11-16 2020-08-28 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
US11067586B2 (en) 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
EP2780717B1 (de) * 2011-11-16 2016-12-21 sphingotec GmbH Adrenomedullintests und verfahren zur bestimmung von reifem adrenomedullin
RS58340B1 (sr) 2011-11-16 2019-03-29 Adrenomed Ag Antitelo na adrenomedulin (adm) ili fragment antitela na adm ili struktura antitela na adm bez ig za regulisanje ravnoteže tečnosti u pacijentu koji ima hroničnu ili akutnu bolest
HUE045940T2 (hu) 2011-11-16 2020-01-28 Adrenomed Ag Adrenomedullinhoz kötõdõ anti-adrenomedullin (ADM) antitest vagy anti-ADM antitest fragmens vagy anti-ADM nem-Ig váz egy páciens akut betegségének vagy akut állapotának kezelésében a keringés stabilizálására történõ alkalmazásra
CA2856136A1 (en) 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
US10598674B2 (en) * 2013-03-20 2020-03-24 Sphingotec Gmbh Adrenomedullin to guide therapy of blood pressure decline
CN106164088B (zh) 2014-03-20 2021-11-23 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
AU2015323769A1 (en) * 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
CN108026182B (zh) 2015-09-18 2022-04-26 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
EP3482208B1 (de) 2016-07-08 2023-04-12 SphingoTec GmbH Adrenomedullin zur beurteilung der kongestion in einer person mit akutem herzversagen
CN110167962B (zh) 2016-12-16 2024-06-07 艾德里诺医药公司 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架
EP3339324A1 (de) 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm)-antikörper oder anti-adm antikörperfragment oder anti-adm-nicht-ig-gerüst zur verwendung in einer intervention und therapie von verstopfung bei einem darauf angewiesenen patienten
EP3604538A4 (de) * 2017-03-29 2020-12-30 University of Miyazaki Adrenomedullinderivat mit langzeitwirkung
EP3438668A1 (de) 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnose und risikostratifizierung von pilzinfektionen
US20220268761A1 (en) 2017-10-18 2022-08-25 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
EP3502706A1 (de) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow für risikobewertung und patientenmanagement unter verwendung von procalcitonin und midregional-proadrenomedullin
SG11202006686SA (en) 2018-02-08 2020-08-28 Sphingotec Gmbh Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
JP2022526507A (ja) 2019-03-29 2022-05-25 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング バイオマーカーに基づく遠隔患者管理の処方
EP3715851A1 (de) 2019-03-29 2020-09-30 B.R.A.H.M.S GmbH Verschreibung von fernpatientenmanagement auf der basis von biomarkern
EP3871689A1 (de) 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antikörper, die an den freien n-terminus binden, für einen beschleunigten übergang von adm-gly zu bio-adm bei patienten mit einem adm-gly/bio-adm-verhältnis über einem schwellenwert und kombination mit vitamin c
CA3172349A1 (en) 2020-02-27 2021-09-02 4TEEN4 Pharmaceuticals GmbH Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock
US20230104578A1 (en) 2020-02-27 2023-04-06 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
CA3112051A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
JP7499533B2 (ja) 2020-04-02 2024-06-14 国立大学法人 宮崎大学 新規アドレノメデュリン類縁体、その製造方法及びその医薬用途
EP4023218A1 (de) 2020-12-02 2022-07-06 S-Form Pharma Kombinationstherapie für patienten mit akuter und/oder anhaltender dyspnoe
WO2022234111A1 (en) 2021-05-07 2022-11-10 Sphingotec Gmbh Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients
WO2024023368A1 (en) 2022-07-29 2024-02-01 4TEEN4 Pharmaceuticals GmbH Prediction of an increase of dpp3 in a patient with septic shock
WO2024023369A1 (en) 2022-07-29 2024-02-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708934A (en) * 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
JPH04282399A (ja) * 1991-03-08 1992-10-07 Fujisawa Pharmaceut Co Ltd 放射性ヨウ素標識インシュリン様成長因子ｉ
HU224350B1 (hu) * 1993-08-09 2005-08-29 Société de Conseils de Recherches et d'ApplicationScientifiques, S.A.S. Á Gyógyhatású peptidszármazékok

Also Published As

Publication number Publication date
AU6064894A (en) 1994-10-27
KR100312443B1 (ko) 2002-02-28
US5910416A (en) 1999-06-08
US5639855A (en) 1997-06-17
EP0622458A2 (de) 1994-11-02
JP2774769B2 (ja) 1998-07-09
EP0622458B1 (de) 2003-01-22
DK0622458T3 (da) 2003-05-19
JPH07196693A (ja) 1995-08-01
DE69432033D1 (de) 2003-02-27
EP0622458A3 (en) 1996-06-12
ES2191674T3 (es) 2003-09-16
AU678212B2 (en) 1997-05-22
US5837823A (en) 1998-11-17
ATE231553T1 (de) 2003-02-15
US5830703A (en) 1998-11-03
CA2122112A1 (en) 1994-10-27
CA2122112C (en) 1999-02-16

Similar Documents

Publication Publication Date Title
ATE231553T1 (de) Adrenomedullin
BR9500732A (pt) Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação
DK150992A (da) Fremgangsmaade til fremstilling af et polypeptidfragment af faktor viii:c, dna-sekvens og ekstrachromosomalt element indeholdende en saadan dna-sekvens, som koder herfor
ATE105867T1 (de) Immunaffinitäts-reinigungssystem.
IE841734L (en) Modified protease inhibitors
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
IL85020A0 (en) Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it
DK611386A (da) Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden
DE69331501D1 (de) Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
KR900700500A (ko) 재조합 유전자 기술에 의한 에라스타제 억제 폴리펩티드 제조방법 및 에라스타제 억제 폴리펩티드
MX167236B (es) Peptidos sinteticos de timosina -1 y metodo para su obtencion
ES8606411A1 (es) Procedimiento para la determinacion de fibrina
EP0725081A4 (de) MONOKLONALER ANTIKÖRPER GEGEN MxA DES MENSCHLICHEN Mx PROTEINS
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
ATE190318T1 (de) Pcna bindende substanz
GB9816514D0 (en) Novel method
EP1117682A4 (de) Peptide
DK450187D0 (da) Fremgangsmaade til fremstilling af proteiner
FI942392A0 (fi) Peptidejä ja vasta-aineita nivelreuman hoitoon
MELOUN et al. Acidic acrosin inhibitors from bull seminal plasma. Structural differences
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
ES504996A0 (es) Un procedimiento para aislar un polipeptido purificado
AR033043A1 (es) Proteina del tipo reg
DK369888A (da) Peptidforbindelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition